Navigation Links
Nile Therapeutics, Inc. to Present at Upcoming BIO Investor Forum
Date:10/2/2007

BERKELEY, Calif., Oct. 2 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (OTC Bulletin Board: SPDU.OB), announced today that Peter M. Strumph, Chief Executive Officer, will present at the Biotechnology Industry Organization (BIO) Investor Forum on Thursday, October 11, 2007 at 12:30 p.m. Pacific Time at The Palace Hotel in San Francisco, California. Mr. Strumph will provide an overview of Nile and an update on its clinical development programs, including data from Nile's recently completed Phase Ia study for its lead compound, CD-NP.

The presentation will be webcast live and can be accessed by visiting the Investor Relations section at http://www.nilethera.com. The webcast will be archived for ninety days. Additional information regarding the BIO Investor Forum can be accessed at http://investorforum.bio.org.

About Nile Therapeutics, Inc.

Nile Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is developing innovative products for the treatment of cardiovascular disease. Nile is initially focusing its efforts on developing its lead compound, CD-NP, a novel chimeric peptide in Phase I studies for the treatment of heart failure and 2NTX-99, a small molecule, pre-clinical, anti-atherothrombotic agent with nitric oxide (NO) donating properties.

CD-NP, a novel chimeric natriuretic peptide currently in Phase I clinical studies for the treatment of heart failure, is a selective NPRB agonist which, in vivo, has been shown to have potent renal enhancement and cardiac unloading properties but with minimal hypotensive effects compared with competitive products. CD-NP is a rationally-designed synthetic peptide designed to incorporate favorable properties of naturally occurring natriuretic peptides. Data from Nile's recently completed Phase Ia study in healthy volunteers confirmed several pre-clinical findings, includin
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO
2. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
3. Wisconsin firms to present at Cleantech venture capital event
4. New Sonic Foundry search engine finds words, phrases in video presentations
5. Lone Wisconsin firm to present at InvestMidwest
6. Sonic Foundry creates search engine for 7,000 expert video presentations
7. InvestMidWest calls for business presentations
8. Wicab to present BrainPort at Boston conference
9. Three more Wisconsin firms to present at venture forum
10. Six Wisconsin firms to present at BIO Mid-America VentureForum
11. New Health and Human Services representative for Midwest
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 22, 2015 Controlled Substance Compliance Services ... helps companies check the legal requirements around using controlled ... China. , As their international operations expand and ... software solutions built as a result of the first ...
(Date:1/22/2015)... Jan. 22, 2015   Cypher Genomics, Inc., ... (NASDAQ: SQNM ), the leading molecular ... next generation noninvasive prenatal tests (NIPT). Through this ... called Mantis™, to advance analysis of clinically-relevant fetal ...
(Date:12/25/2014)... 25, 2014 The report “Service Quality ... Type & Provider Type - Global Advancements, Worldwide Forecasts ... an in-depth analysis and forecasting of revenues. , ... 221 pages and in-depth TOC on “Service Quality Management ...
(Date:12/24/2014)... BOTHELL, Wash. , Dec. 24, 2014   BioLife Solutions ... manufacturer and marketer of proprietary clinical grade hypothermic storage ... thermal shipping products for cells and tissues  ("BioLife" or ... Annual Meeting of Stockholders on May 4, 2015 (the "Annual ...
Breaking Biology Technology:Global Compliance Service for Controlled Substances to Expand to China 2Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 3Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 4BioLife Solutions Sets Date for Annual Meeting of Stockholders 2
... Conference Call Today at 8:30 a.m. EST, SOUTH SAN ... ) today reported financial results for,the three and nine months ... 2008, Rigel reported a net loss of $37.7,million, or $1.03 ... or,$0.61 per share, in the third quarter of 2007. Weighted ...
... Calif., Oct. 31 VNUS(R) Medical,Technologies, Inc. (Nasdaq: ... minimally invasive treatment of venous reflux disease, today,announced the ... Clinical,Research and Chief Medical Officer., Dr. Smeets joins ... joining VNUS, Dr. Smeets served as the Head of ...
... Oct. 31 SleepQuest has always,followed the essence of ... from,undiagnosed and unexplained health problems related to lack of ... the,importance of identifying and treating sleep disorders. Sleep is ... a wellness factor.,Studies done by the National Commission on ...
Cached Biology Technology:Rigel Announces Third Quarter 2008 Financial Results and Clinical Update 2Rigel Announces Third Quarter 2008 Financial Results and Clinical Update 3Rigel Announces Third Quarter 2008 Financial Results and Clinical Update 4Rigel Announces Third Quarter 2008 Financial Results and Clinical Update 5Rigel Announces Third Quarter 2008 Financial Results and Clinical Update 6VNUS Medical Technologies, Inc. Announces the Hiring of Guido Smeets, MD, as Vice President of Clinical Research and Chief Medical Officer 2SleepQuest Tireless in Pursuit of Good Sleep 2
(Date:1/22/2015)... 9, 2015 Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ON), is ... the State of Washington,s Department of ... enrollment and central issuance system for driver,s licenses and identification ... project planning and development will start in January 2015, with ...
(Date:1/22/2015)...  Today, FreeWavz ( www.FreeWavz.com ), the developer of ... Fundable, https://www.fundable.com/freewavz . FreeWavz will be expanding ... meet customer demand. Logo - ... Invented by Dr. Eric ...
(Date:1/22/2015)... , Jan. 15, 2015  BellBrook Labs, a ... discovery, announced the launch of a TR-FRET (time ... company,s Transcreener UDP Assay, a high throughput screening ... new assay will allow for sensitive detection of ...
Breaking Biology News(10 mins):Valid USA Signs Contract For Washington Driver's License Issuance 2FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2
... recent book chapter about sugar-based chemicals is topping ... list. "Sugar-Based Chemicals for Environmentally Sustainable Applications" ... http://pubs.acs.org/doi/abs/10.1021/bk-2010-1061.ch001 and is racking up kudos. ... and research professors A. J. East and W. ...
... treatment processes, in which micro-organisms convert organic matter into ... energy source for heating or electricity. The result is ... the wastewater discharge from polluting industries: pulp and paper, ... with emerging regulations regarding water and waste recycling. ...
... of Florida review of research finds the polyphenol compound known ... may not prevent old age, but it might make it ... a cure for various diseases and a preventative against aging. ... a pill, but it doesn,t exist. But what does exist ...
Cached Biology News:Sugar-based chemicals book chapter by NJIT professor takes ACS kudos 2Water for future generations 2Water for future generations 3UF review of resveratrol studies confirms potential health boost 2UF review of resveratrol studies confirms potential health boost 3
... An immuncapture enzyme-activity assay based on measurenment ... on monoclonal antibody coated microtiter plate. The ... standards, samples or controls, 2nd enzyme ... assay is intended for the determination of ...
... Incubator/Shaker HT is designed for ... Incubator/Shaker HT is ideal for ... and primer extension assays. The ... as a one-cabinet model, allowing ...
... Source: Pseudomonas atlantica Description: Beta-Agarase ... RNA fragments from low-melting-temperature agarose. Beta-Agarase ... disaccharides. Tested User Friendly Properties: Heat ... 30,000 Da Optimum pH: 6.5 Purity: ...
iEMS Thermal Microplate Holder...
Biology Products: